Two recent publications suggest that DeepVariant's machine learning is far superior to traditional methods of variant calling, especially with hardware accelerators.
Othman Laraki, the CEO and co-founder of Color Genomics chats with Barron's Penta.
The company presented Color Data as a resource for variant classification scientists and hopes it will inspire industry peers to similarly share data.
Stat News reports that pharmacogenomics testing in psychiatry may be ahead of the science.
Researchers led by MD Anderson’s Karen Lu want to know the most efficient genetic counseling strategy as more people are getting screened for cancer risk genes.
CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.
Rainbow will offer Color's hereditary cancer and heart health genetic risk assessment tests to patients in Hong Kong.
The study aims to understand the willingness of individuals with a clinical diagnosis of familial hypercholesterolemia and their family members to undergo confirmatory genetic testing.
The firm will provide its genetic testing, counseling, and cascade screening to patients seen at a group of US health systems, focusing on CDC Tier 1 conditions.
The New York Times reports that genetic screening is increasingly offered as an employee benefit.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.